



(12) Translation of
european patent specification

(11) NO/EP 2203173 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/56 (2006.01)
A61K 31/57 (2006.01)
A61K 38/17 (2006.01)
A61P 21/00 (2006.01)
C07J 1/00 (2006.01)
C07J 41/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.04.04
(80)	Date of The European Patent Office Publication of the Granted Patent	2015.12.23
(86)	European Application Nr.	08842559.0
(86)	European Filing Date	2008.10.27
(87)	The European Application's Publication Date	2010.07.07
(30)	Priority	2007.10.26, EP, 07119351 2007.10.26, US, 670 P
(84)	Designated Contracting States:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
(73)	Proprietor	Academisch Ziekenhuis Leiden, Albinusdreef 2, 2333 ZA Leiden, NL-Nederland BioMarin Technologies B.V., J.H. Oortweg 21, 2333 CH Leiden, NL-Nederland
(72)	Inventor	DE KIMPE, Josephus, Johannes, Veilingstraat 175, 3521 BE Utrecht, NL-Nederland PLATENBURG, Gerardus Johannes, Wijngaardenlan 56, NL-Voorschoten 2252 XR, NL-Nederland VAN DEUTEKOM, Judith Christina Theodora, Abeelstraat 13, NL-3329 AA Dordrecht, NL-Nederland AARTSMA-RUS, Annemieke, Navona 42, NL-2134 BE Hoofddorp, NL-Nederland VAN OMMEN, Garrit-Jan, Boudewijn, Westerstraat 73, NL-1015 LW Amsterdam, NL-Nederland
(74)	Agent or Attorney	Zacco Denmark A/S, Arne Jacobsens Allé 15, DK-2300 KØBENHAVN S, Danmark

(54)	Title	MEANS AND METHODS FOR COUNTERACTING MUSCLE DISORDERS
(56)	References Cited:	WO-A-2006/007910 WO-A1-2007/004979 WO-A2-2004/083446 US-A1- 2007 021 360 CHAUBOURT E ET AL: "Muscular nitric oxide synthase (muNOS) and utrophin" JOURNAL OF PHYSIOLOGY - PARIS, vol. 96, no. 1-2, 2002, pages 43-52, XP002469418 RADLEY ET AL: "Duchenne muscular dystrophy: Focus on pharmaceutical and nutritional interventions" INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, EXETER, GB, vol. 39, no. 3, 10 October 2006 (2006-10-10), pages 469-477, XP005831292 ISSN: 1357-2725 SEGALAT L ET AL: "CAPON expression in skeletal muscle is regulated by position, repair, NOS activity, and dystrophy" EXPERIMENTAL CELL RESEARCH, SAN DIEGO, CA, US, vol. 302, no. 2, 15 January 2005 (2005-01-15), pages 170-179, XP004649912 ISSN: 0014-4827 ANDERSON J E ET AL: "Correlated NOS-I and myf5 expression by satellite cells in mdx mouse

muscle regeneration during NOS manipulation and deflazacort treatment" NEUROMUSCULAR DISORDERS, vol. 13, no. 5, 2003, pages 388-396, XP002469419

ARRUDA V R: "The role of immunosuppression in gene- and cell based treatments for Duchenne Muscular Dystrophy" MOLECULAR THERAPY, vol. 15, no. 6, June 2007 (2007-06), pages 1040-1041, XP009096112

GRANCHELLI J A ET AL: "Pre-clinical screening of drugs using the mdx mouse" NEUROMUSCULAR DISORDERS, PERGAMON PRESS, GB, vol. 10, no. 4-5, 1 June 2000 (2000-06-01), pages 235-239, XP002305261 ISSN: 0960-8966

ROLLAND J F ET AL: "Overactivity of exercise-sensitive cation channels and their impaired modulation by IGF-1 in mdx native muscle fibers: Beneficial effect of pentoxifylline" NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 24, no. 3, 1 December 2006 (2006-12-01), pages 466-474, XP024901469 ISSN: 0969-9961 [retrieved on 2006-12-01]

ZHOU GUANG-QIAN; XIE HUI-QI; ZHANG SU-ZHEN; YANG ZHI-MING: "Current understanding of dystrophin-related muscular dystrophy and therapeutic challenges ahead" CHINESE MEDICAL JOURNAL (ENGLISH EDITION), vol. 119, no. 16, 20 August 2006 (2006-08-20), pages 1381-1391, XP002542429

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Kombinasjon av:

- et antisens-oligonukleotid omfattende en sekvens som er komplementær til en del av humant dystrofin-pre-mRNA-ekson 51, og oligonukleotidet er representert ved SEQ ID NO:204

og

- en tilleggsforbindelse for å redusere inflammasjon, hvori denne forbindelsen omfatter et steroid, der kombinasjonen er for bruk som et medikament for å lindre ett eller flere symptom(er) på Duchennes muskeldystrofi hos individet.

2. Kombinasjon for bruk ifølge krav 1, hvori fraværet av eksonet fra mRNA produsert av dystrofin-pre-mRNA-et genererer en kodingsregion for et funksjonelt dystrofin protein.

3. Kombinasjon for bruk ifølge krav 1 eller 2, hvori oligonukleotidet omfattende RNA.

4. Kombinasjon for bruk ifølge krav 3, hvori RNA-et inneholder en 2'-O-metylmodifisert ribose (RNA).

5. Kombinasjon for bruk ifølge krav 3 eller 4, hvori oligonukleotidet er et 2'-O-metyl-fosfortioat- oligoribonukleotid.

6. Kombinasjon for bruk ifølge et hvilket som helst av kravene krav 1 til 5, hvori oligonukleotidet er en peptidnukleinsyresyre, låst nukleinsyresyre, morfolinosfordiamidat eller en hvilken som helst kombinasjon derav.

7. Farmasøytisk preparat omfattende

- en kombinasjon som definert i et hvilket som helst av kravene 1 til 6

og

- en farmasøytisk akseptabel bærer, adjuvant, tynner og/eller eksipient.